Gavorestat is a small molecule commercialized by Applied Therapeutics, with a leading Pre-Registration program in Galactosemia. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Gavorestat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Gavorestat is expected to reach an annual total of $457 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Gavorestat Overview
Govorestat (AT-007) is under development for the treatment of galactosemia in both adult and pediatric patients, Charcot-Marie-tooth disease, sorbitol dehydrogenase deficiency (SORD Deficiency) and PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a. The drug candidate is administered through oral route in the form of suspension. It acts by targeting aldose reductase.
Applied Therapeutics Overview
Applied Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops transformative drugs in areas of Galactosemia and Diabetic Cardiomyopathy (DbCM). The company product pipeline includes include AT-001 a novel aldose reductase inhibitor, AT-007 a SORD Deficiency, AT-001 a Diabetic Peripheral Neuropathy. Applied Therapeutics also develops preclinical pipeline product AT-003, an ARI designed for the treatment of diabetic retinopathy and AT-104 a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukaemia. It serves customers throughout the US. Applied Therapeutics is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$10 million for the fiscal year ended December 2023 (FY2023). The operating loss of the company was US$64.5 million in FY2023, compared to an operating loss of US$83 million in FY2022. The net loss of the company was US$119.8 million in FY2023, compared to a net loss of US$82.5 million in FY2022.
For a complete picture of Gavorestat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
